Department of Pharmaceutical/Medicinal Chemistry , Eberhard Karls University Tübingen , Auf der Morgenstelle 8 , 72076 Tübingen , Germany.
J Med Chem. 2019 Jun 27;62(12):5673-5724. doi: 10.1021/acs.jmedchem.8b01153. Epub 2019 Jan 25.
Targeted covalent inhibitors (TCIs) are designed to bind poorly conserved amino acids by means of reactive groups, the so-called warheads. Currently, targeting noncatalytic cysteine residues with acrylamides and other α,β-unsaturated carbonyl compounds is the predominant strategy in TCI development. The recent ascent of covalent drugs has stimulated considerable efforts to characterize alternative warheads for the covalent-reversible and irreversible engagement of noncatalytic cysteine residues as well as other amino acids. This Perspective article provides an overview of warheads-beyond α,β-unsaturated amides-recently used in the design of targeted covalent ligands. Promising reactive groups that have not yet demonstrated their utility in TCI development are also highlighted. Special emphasis is placed on the discussion of reactivity and of case studies illustrating applications in medicinal chemistry and chemical biology.
靶向共价抑制剂(TCIs)旨在通过反应性基团(所谓的弹头)结合非保守的氨基酸。目前,用丙烯酰胺和其他α,β-不饱和羰基化合物靶向非催化半胱氨酸残基是 TCI 开发中的主要策略。最近共价药物的兴起激发了人们相当大的努力来描述替代弹头,用于非催化半胱氨酸残基以及其他氨基酸的共价可逆和不可逆结合。本文概述了最近用于设计靶向共价配体的除α,β-不饱和酰胺以外的弹头。还突出了尚未在 TCI 开发中证明其效用的有前途的反应性基团。特别强调了讨论反应性以及说明在药物化学和化学生物学中应用的案例研究。